1
|
Secco GB, Fardelli R, Rovida S, et al: Is
intensive follow-up really able to improve prognosis of patients
with local recurrence after curative surgery for rectal cancer? Ann
Surg Oncol. 7:32–37. 2000. View Article : Google Scholar : PubMed/NCBI
|
2
|
Salo JC, Paty PB, Guillem J, Minsky BD,
Harrison LB and Cohen AM: Surgical salvage of recurrent rectal
carcinoma after curative resection: a 10-year experience. Ann Surg
Oncol. 6:171–177. 1999. View Article : Google Scholar : PubMed/NCBI
|
3
|
Pilipshen SJ, Heilweil M, Quan SH,
Sternberg SS and Enker WE: Patterns of pelvic recurrence following
definitive resections of rectal cancer. Cancer. 53:1354–1362. 1984.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Shin SJ, Yoon HI, Kim NK, et al: Upfront
systemic chemotherapy and preoperative short-course radiotherapy
with delayed surgery for locally advanced rectal cancer with
distant metastases. Radiat Oncol. 6:992011. View Article : Google Scholar : PubMed/NCBI
|
5
|
Bosset JF, Collette L, Calais G, et al:
Chemotherapy with preoperative radiotherapy in rectal cancer. N
Engl J Med. 355:1114–1123. 2006. View Article : Google Scholar : PubMed/NCBI
|
6
|
Rodel C, Liersch T, Becker H, et al:
Preoperative chemoradiotherapy and postoperative chemotherapy with
fluorouracil and oxaliplatin versus fluorouracil alone in locally
advanced rectal cancer: initial results of the German
CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 13:679–687.
2012. View Article : Google Scholar : PubMed/NCBI
|
7
|
Baumann M and Krause M: Targeting the
epidermal growth factor receptor in radiotherapy: radiobiological
mechanisms, preclinical and clinical results. Radiother Oncol.
72:257–266. 2004. View Article : Google Scholar : PubMed/NCBI
|
8
|
Ullrich A and Schlessinger J: Signal
transduction by receptors with tyrosine kinase activity. Cell.
61:203–212. 1990. View Article : Google Scholar : PubMed/NCBI
|
9
|
Galizia G, Lieto E, Ferraraccio F, et al:
Prognostic significance of epidermal growth factor receptor
expression in colon cancer patients undergoing curative surgery.
Ann Surg Oncol. 13:823–835. 2006. View Article : Google Scholar : PubMed/NCBI
|
10
|
Porębska I, Harłozińska A and Bojarowski
T: Expression of the tyrosine kinase activity growth factor
receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and
adenomas. Tumour Biol. 21:105–115. 2000. View Article : Google Scholar
|
11
|
Milas L, Mason K, Hunter N, et al: In vivo
enhancement of tumor radioresponse by C225 antiepidermal growth
factor receptor antibody. Clin Cancer Res. 6:701–708.
2000.PubMed/NCBI
|
12
|
Harari PM and Huang SM: Head and neck
cancer as a clinical model for molecular targeting of therapy:
combining EGFR blockade with radiation. Int J Radiat Oncol Biol
Phys. 49:427–433. 2001. View Article : Google Scholar : PubMed/NCBI
|
13
|
Dewdney A, Cunningham D, Tabernero J, et
al: Multicenter randomized phase II clinical trial comparing
neoadjuvant oxaliplatin, capecitabine, and preoperative
radiotherapy with or without cetuximab followed by total mesorectal
excision in patients with high-risk rectal cancer (EXPERT-C). J
Clin Oncol. 30:1620–1627. 2012. View Article : Google Scholar : PubMed/NCBI
|
14
|
Shin HK, Kim M-S, Lee JK, et al:
Combination effect of cetuximab with radiation in colorectal cancer
cells. Tumori. 96:7132010.
|
15
|
Williams KJ, Telfer BA, Stratford IJ and
Wedge SR: ZD1839 (‘Iressa’), a specific oral epidermal growth
factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy
in a human colorectal cancer xenograft model. Br J Cancer.
86:1157–1161. 2002. View Article : Google Scholar : PubMed/NCBI
|
16
|
Häggblad Sahlberg S1, Spiegelberg D,
Lennartsson J, Nygren P, Glimelius B and Stenerlöw B: The effect of
a dimeric Affibody molecule (ZEGFR:1907)2 targeting EGFR
in combination with radiation in colon cancer cell lines. Int J
Oncol. 40:176–184. 2012.
|
17
|
Tan F, Shen X, Wang D, et al: Icotinib
(BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays
potent efficacy in preclinical studies. Lung Cancer. 76:177–182.
2012. View Article : Google Scholar
|
18
|
Shi Y, Zhang L, Liu X, et al: Icotinib
versus gefitinib in previously treated advanced non-small-cell lung
cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority
trial. The Lancet Oncol. 14:953–961. 2013. View Article : Google Scholar
|
19
|
Santivasi WL and Xia F: Ionizing
radiation-induced DNA damage, response, and repair. Antioxid Redox
Signal. 21:251–259. 2014. View Article : Google Scholar
|
20
|
Qu YY, Hu SL, Xu XY, et al: Nimotuzumab
enhances the radiosensitivity of cancer cells in vitro by
inhibiting radiation-induced DNA damage repair. PLoS One.
8:e707272013. View Article : Google Scholar : PubMed/NCBI
|
21
|
Tanaka T, Munshi A, Brooks C, Liu J, Hobbs
ML and Meyn RE: Gefitinib radiosensitizes non-small cell lung
cancer cells by suppressing cellular DNA repair capacity. Clin
Cancer Res. 14:1266–1273. 2008. View Article : Google Scholar : PubMed/NCBI
|
22
|
Herbst RS and Bunn PA Jr: Targeting the
epidermal growth factor receptor in non-small cell lung cancer.
Clin Cancer Res. 9:5813–5824. 2003.PubMed/NCBI
|
23
|
Dittmann K, Mayer C, Fehrenbacher B, et
al: Radiation-induced epidermal growth factor receptor nuclear
import is linked to activation of DNA-dependent protein kinase. J
Biol Chem. 280:31182–31189. 2005. View Article : Google Scholar : PubMed/NCBI
|
24
|
Sano D, Kawakami M, Fujita K, et al:
Antitumor effects of ZD6474 on head and neck squamous cell
carcinoma. Oncol Rep. 17:289–295. 2007.PubMed/NCBI
|
25
|
Rothkamm K and Löbrich M: Evidence for a
lack of DNA double-strand break repair in human cells exposed to
very low x-ray doses. Proc Natl Acad Sci USA. 100:5057–5062. 2003.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Burma S, Chen BP, Murphy M, Kurimasa A and
Chen DJ: ATM phosphorylates histone H2AX in response to DNA
double-strand breaks. J Biol Chem. 276:42462–42467. 2001.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Mah LJ, Orlowski C, Ververis K, Vasireddy
RS, El-Osta A and Karagiannis TC: Evaluation of the efficacy of
radiation-modifying compounds using γH2AX as a molecular marker of
DNA double-strand breaks. Genome Integr. 2:32011. View Article : Google Scholar
|
28
|
Lobrich M, Shibata A, Beucher A, et al:
gammaH2AX foci analysis for monitoring DNA double-strand break
repair: strengths, limitations and optimization. Cell Cycle.
9:662–669. 2010. View Article : Google Scholar : PubMed/NCBI
|
29
|
Ward IM, Difilippantonio S, Minn K, et al:
53BP1 cooperates with p53 and functions as a haploinsufficient
tumor suppressor in mice. Mol Cell Biol. 25:10079–10086. 2005.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Bouwman P, Aly A, Escandell JM, et al:
53BP1 loss rescues BRCA1 deficiency and is associated with
triple-negative and BRCA-mutated breast cancers. Nat Struct Mol
Biol. 17:688–695. 2010. View Article : Google Scholar : PubMed/NCBI
|
31
|
Nuciforo PG, Luise C, Capra M, Pelosi G
and d’Adda di Fagagna F: Complex engagement of DNA damage response
pathways in human cancer and in lung tumor progression.
Carcinogenesis. 28:2082–2088. 2007. View Article : Google Scholar : PubMed/NCBI
|
32
|
Clarke A, Jones N, Pryde F, Adachi Y and
Sansom O: 53BP1 deficiency in intestinal enterocytes does not alter
the immediate response to ionizing radiation, but leads to
increased nuclear area consistent with polyploidy. Oncogene.
26:6349–6355. 2007. View Article : Google Scholar : PubMed/NCBI
|
33
|
Morales JC, Franco S, Murphy MM, et al:
53BP1 and p53 synergize to suppress genomic instability and
lymphomagenesis. Proc Natl Acad Sci USA. 103:3310–3315. 2006.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Li X, Xu B, Moran MS, et al: 53BP1
functions as a tumor suppressor in breast cancer via the inhibition
of NF-κB through miR-146a. Carcinogenesis. 33:2593–2600. 2012.
View Article : Google Scholar : PubMed/NCBI
|
35
|
Park JS, Jun HJ, Cho MJ, et al:
Radiosensitivity enhancement by combined treatment of celecoxib and
gefitinib on human lung cancer cells. Clin Cancer Res.
12:4989–4999. 2006. View Article : Google Scholar : PubMed/NCBI
|